r VTGN Stock Quote - VistaGen Therapeutics, Inc. Stock Price Today
TONIGHT! Join in as Kyle Dennis, 27 year-old,
self-made millionaire, reveals his newest trading strategy.
Days
Hours
Minutes
Seconds

VistaGen Therapeutics, Inc.
(NASDAQ : VTGN)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
-1.14%78.631.2%$618.81m
AMGNAmgen Inc.
0.16%178.241.2%$557.24m
GILDGilead Sciences, Inc.
-0.22%67.380.9%$542.96m
BIIBBiogen Inc.
0.63%286.211.2%$478.24m
REGNRegeneron Pharmaceuticals, Inc.
-0.30%293.742.6%$304.78m
VRTXVertex Pharmaceuticals Incorporated
0.34%157.501.9%$219.69m
ALXNAlexion Pharmaceuticals, Inc.
0.51%117.742.0%$210.05m
ILMNIllumina, Inc.
-1.70%266.223.5%$198.41m
AAgilent Technologies, Inc.
-1.50%63.161.5%$196.40m
NKTRNektar Therapeutics
-0.77%79.966.0%$184.19m
INCYIncyte Corporation
2.64%68.432.5%$149.75m
BMRNBioMarin Pharmaceutical Inc.
4.77%92.494.4%$135.47m
SRPTSarepta Therapeutics, Inc.
1.85%91.6516.6%$126.22m
BLUEBluebird Bio, Inc.
0.62%188.1515.7%$98.65m
EXASExact Sciences Corporation
-1.95%51.8225.5%$98.64m

Company Profile

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative product candidates for patients with diseases and disorders involving the central nervous system. Its product candidate, AV-101, is a next generation, orally available prodrug candidate in Phase 2 development, initially for the adjunctive treatment of Major Depressive Disorder in patients with an inadequate response to standard antidepressants. The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.